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Abstract
Background: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be
refractory to conventional chemotherapy. It is now known that the majority of PLGG have activation of the MAPK/
ERK pathway. The same pathway is also activated in plexiform neurofibromas (PNs) which are low-grade tumors
involving peripheral nerves in patients with neurofibromatosis type 1 (NF1). These lesions are known to be
refractory to chemotherapy. Specific MEK inhibitors such as trametinib are now available and have been approved
for other cancers harboring mutations in the MAPK/ERK pathway such as melanoma. We have observed significant
responses to trametinib in patients with refractory PLGG in our institutions and results from the phase I study are
promising. The treatment appears not only efficacious but is also usually well tolerated. We hypothesize that we will
observe responses in the majority of refractory PLGG and PN treated with trametinib in this phase 2 study.
Methods: The primary objective is to determine the objective response rate of trametinib as a single agent for
treatment of progressing/refractory tumors with MAPK/ERK pathway activation. The TRAM-01 study is a phase II
multicentric open-label basket trial including four groups. Group 1 includes NF1 patients with progressing/refractory
glioma. Group 2 includes NF1 patients with plexiform neurofibroma. Group 3 includes patients with progressing/
refractory glioma with KIAA1549-BRAF fusion. Group 4 includes other patients with progressing/refractory glioma
with activation of the MAPK/ERK pathway. Eligible patients for a given study group will receive daily oral trametinib
at full dose for a total of 18 cycles of 28 days. A total of 150 patients will be enrolled in seven Canadian centers.
Secondary objectives include the assessment of progression-free survival, overall survival, safety and tolerability of
trametinib, serum levels of trametinib and evaluation of quality of life during treatment.
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Discussion: Trametinib will allow us to target directly and specifically the MAPK/ERK pathway. We expect to
observe a significant response in most patients. Following our study, trametinib could be integrated into standard
treatment of PLGG and PN.
Trial registration: ClinicalTrials.gov Identifier: NCT03363217 December 6, 2017.
Keywords: Trametinib, Glioma, Plexiform neurofibroma, Neurofibromatosis type 1, BRAF, MEK inhibitor
Background
Pediatric low-grade gliomas
Pediatric low grade gliomas (PLGG) which include pilocytic
astrocytoma (PA) are the most frequent brain tumors and
represent 25–30% of central nervous system tumors in chil-
dren [1]. While some patients can be cured with surgery
alone, more than 70% need complimentary treatments due
to the location of tumors that preclude resection [2]. Stand-
ard therapy for PLGG includes chemotherapy with a com-
bination of intravenous carboplatin and vincristine, or
weekly vinblastine for 70weeks. Unfortunately, more than
50% of patients will have progressive disease despite conven-
tional treatment(s) [3] [4]. Radiotherapy remains an option,
but this approach has significant long-term side effects in-
cluding cognitive dysfunction, endocrinopathies and vascu-
lopathies [5]. Several clinical trials have focused on
treatments of refractory PLGG but have failed to show sig-
nificant efficacy and there is currently no standard therapy.
Recently, it has been found that the majority of PLGG
have an activation of the MAPK/ERK pathway through-
out various genetic mutations and alterations [6]. The
signaling cascade culminates with ERK translocating to
the nucleus, where it activates transcription factors that
result in gene expression promoting growth and mitosis
[7]. PLGG presents three major genetic alterations
resulting in the activation of the MAPK pathway: NF1
mutation, BRAF fusion and BRAF mutation V600E [6].
NF1 mutations are mainly found in patients with
neurofibromatosis type 1 (NF1). NF1 is one of the most
frequent autosomal dominant diseases and affects 1 in
3000 individuals. Patients with NF1 have a susceptibility
to develop tumor including plexiform neurofibroma
(PN) and PLGG [8]. Up to 20% of NF1 patients will de-
velop optic pathway glioma (OPG) and most of them
will require treatment in order to preserve visual integ-
rity [9]. NF1 patients can also develop PA in various lo-
cations such as the brainstem and subcortical areas [10].
The BRAF V600E mutation lies in the kinase domain and
results in a constitutive activation of the MAPK/ERK path-
way. The V600E mutation is positive in 5–10% of PA usu-
ally involving the brainstem and deep gray nuclei [11] [12].
The fusion between KIAA1549 (an uncharacterized
gene) and the BRAF oncogene was reported to be a com-
mon feature of PA [13]. This fusion results in a constitu-
tive activation of BRAF kinase activity with the loss of the
BRAF N-terminal autoregulatory domain [14]. The
KIAA1549:BRAF fusion is found in up to 77% of PA [15].
Finally, other mutations in PLGG were also found to
activate the MAPK pathway through rare BRAF fusions
or mutations, kinase domain duplications of FGFR1, and
fusions of the NTRK gene (reviewed in Sturm et al., JCO
2017) [6, 16, 17]. Clinical implication of each mutation
in terms of progression and response rate is currently
unknown.
NF1 with Plexiform Neurofibroma
Up to 50% of NF1 patients will develop plexiform neuro-
fibromas (PNs) which affect large peripheral nerves [18, 19].
Despite distinctive histology and location of PNs when com-
pared to PLGG, there is also an activation of the MAPK/
ERK pathway through NF1 mutations.
PNs usually progress relentlessly during childhood, ado-
lescence and adulthood causing lifelong disfigurement,
disability, and mortality [18]. PNs can compress vital or-
gans and create an array of morbidities.
Treatment of PNs consists primarily of symptoms man-
agement and/or surgical resection. However, the tumor’s
close involvement with nerve, vasculature, or other viscera
complicates surgery with ensuing frequently incomplete
resection followed by tumor re-growth, or morbidity. Al-
though several molecularly targeted compounds are in
preclinical and clinical studies, but there is currently no
approved medical therapy or cure for PNs.
Targeting the MAPK/ERK pathway
Because of its key activation in PLGG, targeting the
MAPK/ERK with small molecules offers new therapeutic
possibilities.
Dabrafenib, a selective BRAF inhibitor, was shown to
be effective in PLGG with BRAF V600E mutations [20].
Additionally, a phase II clinical trial with dabrafenib and
trametinib for patients with PLGG and high-grade gli-
oma with V600E mutation is underway (NCT02684058).
However, patients that hold BRAF fusions treated with
sorafenib alone had an acceleration of tumor growth
likely related to paradoxical ERK upregulation [21]. As
such, MEK inhibitors, which act further down in the
molecular pathway, may be a better treatment alternative
for these patients.
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Recently, phase I and II study with selumetinib (an-
other MEK inhibitor) showed promising antitumor ac-
tivity in PLGG [22] [23] and Dombi et al. demonstrated
dramatic responses in patients with PN treated with
selumetinib [24]. However, this agent is still under inves-
tigation, is not available in Canada and has not been ap-
proved yet for treatment of PN or PLGG.
Trametinib
Trametinib is a reversible, highly selective allosteric inhibi-
tor of MEK1/MEK2 activation and kinase activity. It has
good oral bioavailabily (72%). Food can decrease trametinib
AUC by 24% and Cmax by 70%, so it is recommended to
be administered under fasting conditions, either 1 h before
or 2 h after a meal. It is highly bound to plasma proteins
(97%). It is metabolized mainly via deacetylation alone
(non-CYP mediated) or with mono-oxygenation in combin-
ation with glucuronidation. In vitro, trametinib is an inhibi-
tor of CYP2C8, an inducer of CYP3A4 and a substrate of
P-gp, but no significant drug interaction has been identified.
It is mainly eliminated via the feces (≥ 80%), and to a lesser
extent in urine (< 20%), mainly as inactive metabolites. Less
than 0.1% of the parent drug is recovered in the feces and
the urine. Ouellet et al. observed that trametinib oral clear-
ance was lower in women compared to men (1.26-fold)
and increased with body weight [25]. The half-life of trame-
tinib is 5.3 days after a single dose administration and
steady state is achieved by day 15. So far, all pharmacokin-
etics data are coming from adult studies, but there are on-
going studies evaluating pharmacokinetics data in pediatric
populations. Available formulations and strengths are tra-
metinib 0.5mg tablets, trametinib 2mg tablets and trameti-
nib powder for oral solution (0.05mg/mL). Cox et al.
evaluated the bioavailability of the oral solution compared
with the tablet formulation. They found similar AUCs, but
the Cmax of the oral solution was higher and the Tmax
earlier compared to the tablet formulation [26]. In Canada,
trametinib was approved as monotherapy in 2013 and in
combination with dabrafenib in 2016 for the treatment of
adult patients with unresectable or metastatic melanoma
with a BRAF V600E mutation [27] [28].
Grossauer et al. demonstrated the efficacy of trameti-
nib in murine xenografts with V600E high grade glioma
[12]. Recently, Geoerger et al. presented results of their
phase I for safety and tolerability of trametinib in
pediatric patients with refractory solid tumors [29].
Overall, trametinib was well tolerated with relatively few
side effects. Among patients treated with trametinib
monotherapy, hyponatremia (n = 2) and pyrexia (n = 2)
were the only treatment-related serious adverse events
(SAEs) reported in > 1 patients. The recommended dose
was 0.025 mg/kg daily for patients of 6 years and older
and 0.032 mg/kg for patients younger than 6 years old.
This study was not designed to assess efficacy of
trametinib but it was reported that in 40 of the patients
with LGG or NF1-related PN, 7 showed partial response
(PR), 21 patients had stable disease (SD) and only 4 had
progressive disease (PD). Seven patients were not evalu-
able. It is not reported at this date how many patients
with SD were considered having a minor response (MR)
(decrease in lesion size of > 25% to ≤50%).
In case reports, tumors with KIAA1549:BRAF fusion were
found to be very sensitive to trametinib [30]. In our series of
six patients treated with trametinib, one showed PR, four
had MR and only one had PD [31]. Our observations are in
line with what Geoerger reported in their phase I study [29].
Study rationale
Since there is no standard treatment for refractory PLGG
and limited conventional chemotherapy regimens, we de-
veloped a study to target the MAPK/ERK pathway. Tra-
metinib was selected because of its bioavailability, long
half-life and availability in a liquid oral solution (currently
only available for clinical trial). This drug has also been
used on a compassionate basis for PLGG patients over the
years in our centers. While designing this study, we in-
cluded a specific group for NF1 patients with PN since
treatment with trametinib is also promising for this popu-
lation. A classical randomized clinical trial could not be
conducted since there is no standard efficacious second-
line treatment and the use of a placebo would not be eth-
ical in this situation. We therefore designed an open label
modified phase II basket trial with four patient groups.
Methods/design
Objectives
The primary objective is to determine the response rate
of daily trametinib as a single agent for treatment of pro-
gressing/refractory tumors with MAPK/ERK pathway ac-
tivation. The response rate is defined as the proportion
of patients with stable disease (SD), minor response
(MR), partial response (PR) and complete response (CR)
as the best response on study.
Secondary objectives include:
 Determine efficacy outcome defined as time to
progression (TTP), progression free survival (PFS)
and overall survival (OS) up to three years following
completion of treatment.
 Determine the safety and tolerability of trametinib.
Adverse events (AE) and severe adverse events
(SAE) will be monitored.
 Analyse the serum levels of trametinib. Analysis of trough
level will be done twice (at day 22, and before starting
cycle 16 or at progression whichever comes first).
 Assess changes in quality of life over treatment phases
and compare pre and post changes across groups.
Evaluations of quality of daily life will be recorded at
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inclusion and every six months with the Pediatric
Quality of Life Inventory (PedsQL) (Generic Core
Scales/Brain tumor modules/Infant Scales).
Exploratory objectives include:
 Determine if there are cognitive changes in patients
with NF1 during treatment with trametinib.
Neurocognitive assessment will be performed at
inclusion and at completion of treatment using:
Bayley-III, D-KEFS, WPPSIV, WISC-V and WAIS-IV
depending on the age of patients with NF1.
 To investigate and correlate biological features to
tumor response. Gene expression profiling will be
done on fresh frozen tissue and mutational analysis on
paraffin-embedded tissue. Circulating tumor DNA in
blood (ctDNA) will be assessed throughout treatment.
Study design
The TRAM-01 study is a phase II open-label basket trial.
A total of seven pediatric academic hospitals will be par-
ticipating. Four groups of patients will be included.
Group 1 includes NF1 patients with progressing/refrac-
tory glioma. Group 2 includes NF1 patients with plexi-
form neurofibroma. Group 3 includes patients with
progressing/refractory glioma with KIAA1549-BRAF fu-
sion. Group 4 includes other patients with progressing/
refractory glioma with activation of the MAPK/ERK
pathway. Mutational status is determined locally in par-
ticipating institutions and will be confirmed centrally.
Ethical consideration
Full ethical approval for the study was obtained from the
Research Ethics Committee from CHU Sainte-Justine.
The TRAM-01 study will be conducted according to the
principles of the Declaration of Helsinki. Written con-
sent to participate will be obtain from participant or par-
ents/legal guardians for minors. Data management,
monitoring and reporting of the study will be performed
in accordance with the ICP-GCP guidelines.
Inclusion criteria
1. Consent. Signed written informed consent prior to
study participation
2. Assent. Assent from minor participants will be sought
3. Study activities compliance. Participants must be
willing and able to comply with scheduled visits,
treatment schedule, laboratory testing, and other
requirements of the study, including disease
assessment by contrast-enhanced MRI
4. Age. Patients must be aged ≥1 month (corrected
age) to ≤25 years at the time of study enrollment
5. Study group. Participants must belong to one of the
following groups to be eligible
 Group 1: NF1 with progressing/refractory LGG
 Group 2: NF1 with PN
 Group 3: Progressing/refractory LGG with
KIAA1549-BRAF fusion.
 Group 4: Progressing/refractory glioma with
activation of the MAPK/ERK pathway who do
not meet criteria for other study groups.
6. Tumor Tissue. Sample Tumor tissue will be required for
all patients (fresh tissue recommended when available).
Patients with NF1 and LGG or PN can still be enrolled
without tissue if no surgery or biopsy was conducted.
7. Previous MRI. At least two previous MRI for Group
1, 3, 4 and one previous MRI for Group 2 must be
available for central review.
8. Prior therapy. Participants must have failed at least
one line of treatment including chemotherapy and/
or radiation therapy except for plexiform
neurofibroma (since there is no recognized standard
treatment for this tumor).
9. Prior therapy toxicity. Patients must have recovered
to grade ≤ 1 from acute toxic effects of all prior
chemotherapy, immunotherapy or radiotherapy prior
to enrollment. Toxicities will be graded as per the
National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE), version 5.0.
10. Prior therapy timeline. Participants having
previously received a chemotherapy agent(s) and/or
radiation must conform to the timeline described
below. There is no limitation on the number of
previous treatments or cycles received.
 An interval of at least 28 days after the last dose
of a myelosuppressive chemotherapy, and at
least 42 days after the last dose of Nitrosoureas is
required prior to starting trametinib.
 An interval of at least 28 days after the last dose
of any biologic agents including monoclonal
antibody treatment, immunotherapy, viral
therapy and other investigational agent is
required prior to starting trametinib.
 An interval of at least 84 days after the end of
radiation therapy is required prior to starting
trametinib.
 An interval of at least 48 h for short-acting
colony stimulating factor agents and 10 days
interval for long-acting colony stimulating factor
agents are required prior to starting trametinib.
11. Life expectancy. Patients must have a life
expectancy of greater than 6 months.
12. Performance level. Patients must have a
performance status corresponding to a Lansky/
Karnofsky score ≥ 50.
13. Organ Function Requirements.
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Participants must have normal organ and marrow
function as defined below:
 Total leukocytes ≥3000/μL
 Absolute neutrophil count (ANC) ≥ 1000/μL
 Hemoglobin > 80 g/l (transfusion independent within
last 2 weeks)
 Platelet count ≥100,000/μL (transfusion independent
within last 2 weeks)
 Total bilirubin ≤1.5 times the upper limit of normal
(ULN) within normal institutional limits for age
 Alanine Aminotransferase (ALT) ≤ 2.5 times the
upper limit of normal (ULN)
 Serum creatinine within normal institutional limits
for age OR creatinine clearance ≥60 mL/min/1.73 m2
for participants with creatinine levels above
institutional normal.
 Creatine phosphokinase ≤2x ULN
 A cardiac function defined as Corrected QT (QTcB)
interval < 480 msec and LVEF ≥ lower limit of
normal (LLN) by echocardiogram (ECHO).
 Blood pressure must be smaller or equal to the 95th
percentile for patient’s age, height and gender.
14. Reproductive status. Children of childbearing and
child-fathering potential must agree to use adequate
contraception. Males and females treated or en-
rolled in this protocol must also agree to use ad-
equate contraception prior to the study, for the
duration of study participation, and 6 months after
completion of trametinib administration.
15. Administration of oral medication. Patients must be
able to ingest and retain enterally (per os,
nasogastric tube or gastrostomy) administered
medication and be free of any clinically significant
gastrointestinal abnormalities limiting the
absorption of the medication. Tablets cannot be
crushed. If the patient cannot swallow tablets, the
liquid form should then be used.
Exclusion criteria
1. Other investigational agents. Patients who are
receiving any other investigational agents.
2. Cardiac exclusion criteria. Patient who has an
ejection fraction inferior to the institution LLN, a
QTcB ≥480 msec or an absolute resting left
ventricular ejection fraction (LVEF) of ≤39% are not
eligible for enrolment.
3. Presence of another malignancy. Patient has any
other malignancy except if the other primary
malignancy is neither currently clinically significant
nor requiring active intervention
4. Previous MEK inhibitor treatment. Participants
previously treated with a MEK inhibitor who
showed less than stable disease during treatment
5. Tumor with BRAF V600E mutation. Patients with a
tumor presenting a positive BRAF V600E mutation
6. Other uncontrollable medical disease. Patient who
has a severe and uncontrollable medical disease, has
a chronic liver disease, uncontrolled intercurrent
illness including, but not limited to, ongoing or
active infection, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia,
or psychiatric illness/social situations that would
limit compliance with study requirements
7. Known HIV infection. Patient who has a known
diagnosis of human immunodeficiency virus (HIV)
infection, hepatitis B or C
8. Previous surgery. Patients who had major surgery
within 2 weeks prior to study entry
9. Allergy. History of allergic reactions attributed to
compounds of similar chemical or biologic
composition to trametinib
10. Previous history of non-compliance. Patients with a
previous significant history of non-compliance to
their treatment or medical regimen
11. Pregnant or breastfeeding patients. Pregnant or
breastfeeding female patients are not eligible for this
study
Sample size
We expect to recruit a total of 150 (Group 1 and 3 = 42
patients each, Group 2 = 46 patients and Group 4 = 20 pa-
tients). Sample size was calculated based on the assump-
tion that trametinib will be considered inactive if the true
response rate is 40% or less; however, if the true response
rate is 60% or more, then this treatment would be consid-
ered worthy of further study. Therefore, set H0: response
rate = 0.40 (lower limit) versus HA: response rate = 0.60.
Simon optimal model was used. For Groups 1, 2 and 3 a
minimum of 39 patients is needed in order to support or
reject H0. Since 42 patients will be enrolled in Groups 1
and 3 and 46 patients in Group 2 this will account for
non-compliance and loss to follow-up of 7 and 15%
respectively. Group 4 will be looking at the feasibility to
include and treat patients without NF1 and KIAA1549-
BRAF fusion. If the recruitment cannot be completed for
any reason, participants in Groups 1, 3 and 4 can be
pooled to test H0 for PLGG.
Intervention
During the treatment phase, patients will receive trame-
tinib at a fixed dose of 0.025 mg/kg (patients ≥6 years) or
0.032 mg/kg (patients < 6 years) with no dose escalation.
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Trametinib will be administered for up to 18 cycles of
28 days to assess the efficacy and safety in patients with
PLGG or PN. Patients weighting < 33 kg or who cannot
swallow tablets will receive the oral solution. Available
formulations and strengths are trametinib 0.5 mg tablets,
trametinib 2 mg tablets and trametinib powder for oral
solution (0.05 mg/mL). For toxicity related to trametinib,
one dose reduction will be accepted. The need for a sec-
ond dose reduction will lead to the permanent discon-
tinuation of study treatment. Specific guidelines are
available in the protocol for management of toxicity.
Follow-up phase
Patients will be followed every six months for up to 3 years
post-treatment or progression. They will be followed for
overall survival, further progression and information on
further lines of anti-cancer treatments; if known, dates of
initiation and end dates will be collected.
Data collection
All data for the TRAM-01 study is entered in a customized
Electronic Data Capture system developed by Information
Management Systems (IMS) at the Lady Davis Institution.
Radiological evaluation
MRI will be done at screening and every 3 cycles during
treatment phase and every six months during the follow-
up period.
Baseline lesions and responses for Groups 1, 3 and 4
will be evaluated using the modified Response Assess-
ment in Neuro-Oncology (RANO). Target lesion(s) must
measure at least 10 mm by 5mm.
 Complete Response (CR) - No radiological evidence
of tumor on MRI scans.
 Partial Response (PR) - Greater than 50% reduction
in the sum of the product of the greatest tumor
diameter and its perpendicular diameter taking as
reference the baseline measurements by MRI scan.
 Minor Response (MR) - 25-50% reduction in the
sum of the product of the greatest tumor diameter
and its perpendicular diameter taking as reference
the baseline measurements by MRI scan.
 Stable Disease (SD) - Less than a 25% decrease or ≤
25% increase in the sum of the product of the
greatest tumor perpendicular diameters taking as
reference the smallest measurement since treatment
started by MRI scan.
 Progressive Disease (PD) - Greater than a 25%
increase in the sum of the product of the greatest
tumor perpendicular diameters in the tumour size
by MRI taking as reference the smallest
measurement since treatment started by MRI scan,
or appearance of one or more new tumoral lesion in
a previously uninvolved area on MRI scan.
Baseline lesions and responses for Group 2 will be
evaluated using a modified Response Evaluation Criteria
in Solid Tumors (RECIST 1.1). Target lesion(s) must
measure at least 30 mm in on direction.
 Complete Response (CR)- No radiological evidence
of tumor on MRI scans.
 Partial Response (PR) - Greater than 50% reduction
in the sum of the greatest tumors diameters on MRI
scan taking as reference baseline measurements.
 Minor Response (MR) - 25-50% reduction in the
sum of the greatest tumors diameters on MRI scan
taking as reference baseline measurements.
 Stable Disease (SD) - Less than a 25% decrease or ≤
25% increase in the sum of the greatest tumors
diameters taking as reference the smallest
measurement since treatment started.
 Progressive Disease (PD) - Greater than a 25%
increase in the sum of the greatest tumors diameters
taking as reference the smallest measurement since
treatment started or appearance of one or more new
tumoral lesion in a previously uninvolved area.
All treatment responses throughout this study will be
centrally reviewed by an independent radiologist.
Neuropsychological evaluation
Neuropsychological evaluations will be conducted to as-
sess cognitive function at start of treatment +/− 28 days,
and at the end of treatment (between cycle 17 and the
end of cycle 18) for NF1 patients (Groups 1 and 2 pa-
tients only). Testing battery will depend on age at inclu-
sion (Bayley III < 3 years old, WPPSIV ≥3 to 5 years old,
WISC-V ≥ 6 to 16 years old, WAIS-IV for ≥17 years old
and D-KEFS for ≥8 years old).
Quality of life evaluation
To document the quality of life of patients, the PedsQL
Generic scale and Brain Tumor module [32–34]. The mea-
sures are available over the age span with an infant scale for
patients under 2 years will be used to assess the physical,
mental, social health dimensions, as well as the cognitive
development of children [35]. The PedsQL integrates the
generic and disease-specific approaches with child self-
reports and parent proxy-reports [36]. Thus, both question-
naires will be completed by the patient and one caregiver.
Biological study
To determine study group, the NF1 diagnosis will be
confirmed clinically based on NIH criteria or by genetic
testing. KIAA1549-fusion will be confirmed by FISH or
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CGH in local institution. V600E mutation will be ex-
cluded by immunohistochemistry staining or RT-PCR.
Next generation sequencing will be done in the form of
RNAseq and as needed a targeted panel (if no alteration
is identified in RNAseq). All genetic alterations will be
validated. DNA methylation assay using the 850 K array
will be performed.
Statistical analysis
A two-stage assessment during recruitment will be
conducted.
For Groups 1 and 3, assuming alpha = 0.05 and
power = 0.70:
During Stage 1, 11 patients will be accrued. Group will
continue to Stage 2 if ≥6 patients have an objective re-
sponse (total of best responses = SD +MR + PR + CR).
During Stage 2, if ≤21 patients have an objective re-
sponse, the treatment will be deemed inactive.
For Group 2, assuming alpha = 0.05 and power = 0.80:
During Stage 1, 16 patients will be accrued. Group will
continue to Stage 2 if ≥8 patients have an objective re-
sponse (total of best responses = SD +MR + PR + CR).
During Stage 2, if ≤23 patients have an objective re-
sponse, the treatment will be deemed inactive.
Objective responses will be listed by patient and time-
point; best response on study, TTP, PFS, and OS will be
reported by patient. Descriptive summary statistics for
each group will be presented for TTP, PFS, and OS.
Curves for PFS, TTP, and OS may be estimated using
Kaplan-Meier methods.
Safety
Scientific evaluation was done at Sainte-Justine by an in-
dependent committee prior to submission to research
ethics board (REB). The first ethical review was con-
ducted at CHU Sainte-Justine.
An independent and outside ARO (academic research
organization), Exactis Innovation, has been assigned for
the management of this study. Exactis will be responsible
for overseeing the regulatory aspects and, monitoring of
sites, verify compliance and conduct site visits.
We will record all AEs and SAEs to better evaluate tol-
erability. The descriptions and grading scales found in
the revised CTCAE version 5.0 will be used. Manage-
ment of AEs of special interest is well described in the
protocol. In order to detect early signs of toxicities, sur-
veillance exams will include regular ophthalmologic
evaluations, EKG, echocardiogram and X-ray of the
growth plate. All SAEs must be reported within 24 h
after the Investigator is made aware.
A Data Safety Monitoring Board (DSMB) was created
following the study approval. DSMB will be tasked with
determining safe and effective conduct of the study and
with recommending the date for the conclusion of the
trial based upon whether significant benefits or risks
have developed. All members composing the DSMB are
independent from the research team and free of any
conflicts of interest.
A Data Monitoring Committee (DMC) will receive
and review the progress and accrual data of this trial and
will safeguard the interests of trial participants, periodic-
ally review and evaluate the accumulated study data for
participant safety and efficacy and monitor the progress
and overall conduct of the clinical trial. The DMC has
access to quarterly study reports, raw study data so that
they can see any emerging risks such as frequent or se-
vere adverse events.
Discussion
Based on ongoing phases I and II trial with MEK inhibi-
tors and case series, trametinib is a potential efficacious
therapy for PLGG with activation of the MAPK/ERK
[30, 31] [29]. We designed this study to confirm trameti-
nib efficacy, safety and assess the duration of response
once the trametinib is stopped. There is currently no
other similar or competing clinical trial for patients with
PLGG. In fact, this is the first and only phase II clinical
trial to use trametinib as a single agent for low grade gli-
oma and/or plexiform neurofibroma. We decided to
subdivide our glioma cohort into three distinct groups
since response rate might vary depending on the mo-
lecular alteration. For example, NF1 patients might
present a better response to trametinib compared to
KIAA1549-BRAF fusion patients. Our group 4 includes
patients with a MAPK/ERK activation (not NF1,
KIAA1549-BRAF, or BRAF V600E) who could benefit
from a MEK inhibitor. This group can include patients
with KRAS mutation, rare fusion or BRAF mutation for
example. This group will be heterogeneous in terms of
molecular profile and will be exploratory.
Patients with NF1 and a plexiform neurofibroma are
also likely to respond to trametinib. These patients will
be included in a specific subgroup. However, dosing,
duration of treatment, surveillance and management of
side effects are essentially the same than in patients with
glioma and this population was therefore included in
this study.
During this study, we will evaluate not only standard
response and toxicity, but we also include important
outcomes such as quality of life. Indeed, late
psychological-related effects have been demonstrated in
pediatric low-grade gliomas, such as the reduction of
health-related quality of life (HRQOL) [37]. Surveillance
of HRQOL during treatments is essential, especially as
brain tumor patients have reported a poor HRQOL [34].
In our experience, daily oral trametinib is better toler-
ated than weekly vinblastine or vincristine/carboplatin
regimen.
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Neurocognitive assessment of patients with NF1 re-
ceiving trametinib will be conducted. Based on our expe-
riences we believe that young patients with NF1 might
show improvement in their development milestones
while receiving trametinib. Our study is not powered to
specifically answer this hypothesis but these investiga-
tions may give us data supporting a future clinical trial
dedicated to this important issue.
Finally, molecular analysis will allow us to better
understand why most patients respond to treatment
whereas a minority progress. Gliomas with specific mu-
tations or methylation profiles might have better and
more sustained response to trametinib.
Appendix I
Planned Participating centres with local investigator
in alphabetical order.
Alberta Children’s Hospital, Calgary, AB (Lucie Lafay-
Cousin MD).
BC Children’s Hospital, Vancouver, BC (Juliette Hukin
MD).
CHU Sainte-Justine, Montréal, QC (Sébastien Per-
reault MD).
CHU de Québec, Québec City, QC (Valérie Larouche
MD).
Hospital for Sick Children’s-SickKids, Toronto, ON
(Eric Bouffet MD).
IWK Health Centre, Halifax, NS (Craig Erker MD).
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